# Procter & Gamble Health share price today (Procter & Gamble Health Ltd, NSE: PGHL)

> Procter & Gamble Health share price today: ₹5,859.00 at the NSE close on 3 November 2026, down 5.0% in a year. Procter & Gamble Health (NSE: PGHL) is worth ₹9,727 crore, trades at a P/E of 29.1 and has closed between ₹4,778.60 and ₹6,839.00 over the past 52 weeks. > Procter & Gamble Health Ltd's earnings have grown faster than its share price. Earnings per share grew +39.5% in a year while the price moved −5.0%. PGHL · Pharma - MNC bulk Drugs · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/procter-gamble-health-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹5,859.00 (−5.0% in a year)
- P/E: 29.1× (lower than 68% of the last 11 years)
- Revenue (Jun 2026): ₹364 Cr (+7.4% on a year ago)
- Profit (Jun 2026): ₹96.0 Cr (+45.5% on a year ago)
- Operating margin: 27.0% (flat on a year ago)
- ROCE: 84%, Mar 2026
- ROIC: 101.0%, against a 12.0% cost of capital: +89.0 points

The main question: yearly earnings per share moved +39.5% while the share price moved −5.0%. ## What is the Procter & Gamble Health share price today? Procter & Gamble Health Ltd's share price was ₹5,859.00 at the close on 3 November 2026. It has been falling for 4 weeks. That is 3.3% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. In the last 52 weeks it traded between ₹4,779 and ₹6,839, and at that close it sat 52% of the way up from that low. Over the last 11 years the share price moved +792% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Procter & Gamble Health this quarter? Two changes stood out: revenue up on a year earlier for 6 quarters in a row and highest quarterly profit in 15 quarters. 1. Revenue up on a year earlier for 6 quarters in a row In the June 2026 quarter revenue was ₹364 crore, +7.4% on a year earlier. 2. Highest quarterly profit in 15 quarters Profit of ₹96 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are Procter & Gamble Health's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Procter & Gamble Health reported revenue of ₹364 crore, up 7.4% from ₹339 crore a year earlier, and a profit of ₹96.0 crore, up 45.5% from ₹66.0 crore. ### Procter & Gamble Health results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹364 crore | ₹339 crore | +7.4% |
| Profit | ₹96.0 crore | ₹66.0 crore | +45.5% |
| Earnings per share | ₹57.92 | ₹39.87 | +45.3% |
| Operating margin | 27.0% | 27.0% | 0.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 18 June 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Procter & Gamble Health share price history? Procter & Gamble Health closed at ₹5,859.00 on 3 November 2026, down 5.0% from ₹6,166.50 a year earlier (31 October 2025) and up 7.6% over five years. Its highest weekly close since March 2016 was ₹7,379.45 on 12 February 2021. ### Procter & Gamble Health share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹5,015.00 | +16.8% |
| 1 month ago · 1 Oct 2026 | ₹5,360.00 | +9.3% |
| 6 months ago · 30 Apr 2026 | ₹5,216.90 | +12.3% |
| 1 year ago · 31 Oct 2025 | ₹6,166.50 | −5.0% |
| 3 years ago · 3 Nov 2023 | ₹5,137.60 | +14.0% |
| 5 years ago · 4 Nov 2021 | ₹5,444.20 | +7.6% |
| 10 years ago · 4 Nov 2016 | ₹792.40 | +639.4% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹657.20 | +791.5% |
| Highest weekly close since March 2016 · 12 Feb 2021 | ₹7,379.45 | −20.6% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹643.85 | +810.0% |
| 52-week high (weekly close) · 10 Jul 2026 | ₹6,839.00 | −14.3% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹4,778.60 | +22.6% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Procter & Gamble Health? 3 Nov 2026: Procter & Gamble Health closed at ₹5,859.00, up 16.8% on the week and up 9.3% on the month. 27 Aug 2026: ex-date for a dividend of ₹45 a share. ### Earlier

- Our read, 19 Jul 2026: With margins at cycle highs, any pricing pressure or input cost inflation will severely compress earnings. - Results for April to June 2026: Revenue up 7.4% and profit up 45.5% on a year earlier. - 18 Jun 2026: Procter & Gamble Health held its results call for January to March 2026. Management guided: Growth momentum expected sustainable through near-term. - 12 Feb 2026: ex-date for an interim + special dividend of ₹160 a share. ### Our read of the business

With margins at cycle highs, any pricing pressure or input cost inflation will severely compress earnings. (Our read after the January to March 2026 results, written 19 July 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What dividend does Procter & Gamble Health pay? Procter & Gamble Health paid ₹155 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 2.65% at the ₹5,859.00 close on 3 November 2026. The last was a dividend of ₹45 a share, ex-date 27 August 2026. ### Procter & Gamble Health dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 27 Aug 2026 | ₹45 | Dividend | same day |
| 12 Feb 2026 | ₹160 | Interim + Special | same day |
| 22 Aug 2025 | ₹45 | Dividend | same day |
| 21 Feb 2025 | ₹80 | Interim | same day |
| 28 Nov 2024 | ₹60 | Dividend | n/a |
| 14 Feb 2024 | ₹200 | Interim + Special | same day |
| 23 Nov 2023 | ₹50 | Dividend | n/a |
| 13 Feb 2023 | ₹45 | Interim | same day |
| 15 Nov 2022 | ₹11.50 | Dividend | n/a |
| 12 May 2022 | ₹41 | Interim | 13 May 2022 |
| 2 Nov 2021 | ₹130 | Dividend + Special | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

₹50 Special dividends, last 12 months

Yes. Procter & Gamble Health Ltd paid out 104% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Procter & Gamble Health management say on the latest results call? On the call for January to March 2026, held on 18 June 2026, Procter & Gamble Health's management guided: Growth momentum expected sustainable through near-term. > “For the 12-month fiscal year ended March 31, 2026, we reported sales of close to Rs 1,400 crores, which is up 16% versus the comparable period last year. The profit after tax was Rs 327 crores, which is up by 30% versus the comparable period last year.”
> Milind Thatte, on the call for January to March 2026

### What management guided

- FY26 growth composition disclosed: mid-single digit volume contribution, remainder from pricing and product mix. - NPPA pricing framework parameters: 10% maximum annual increase non-scheduled drugs, WPI-indexed increases for scheduled drugs. - Innovation pipeline continuing with consumer-centric focus but details kept confidential. - Margin trajectory: balanced approach to top-line and bottom-line growth with 30% profit growth in FY26 demonstrating capability. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/89/Conference Call/CC-Jun26.pdf). (From the call for January to March 2026, 18 June 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What could change the Procter & Gamble Health story? What are the risks? Sustained operating margin at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical. ### Each change stops working if

- : Consumer downtrading or increased competition in OTC wellness. ### The main risks

- : Severe earnings compression if margins mean-revert. ⚠ estimate

(Our read after the January to March 2026 results, written 19 July 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Procter & Gamble Health's next results? When Procter & Gamble Health reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Livogen Iron Gummies market position retention - achieved #1 Amazon category share in FY26; monitor Q1/H1 FY27 online channel data for whether position lasts and continues contributing growth; management emphasized exceeding expectations. - What to check (from the call)
- Livogen Iron Gummies market position retention - achieved #1 Amazon category share in FY26; monitor Q1/H1 FY27 online channel data for whether position lasts and continues contributing growth; management emphasized exceeding expectations. - Neurobion Cream prescription share uptake post-HCP education - medically trained salesforce educated 1 lakh HCPs in FY26 on nerve pain solutions; watch Q1/H1 FY27 data or next-call disclosure on whether recommendation-to-prescription conversion materializing as intended. - Extra-urban pharmacy penetration pace - added approximately 30,000 pharmacies over 2-3 years as core growth lever; monitor next call for FY27 addition rate commentary (continuing similar 10-15k annual pace or accelerating) with management stating momentum will continue picking up. ## Which stock lists is Procter & Gamble Health on? Procter & Gamble Health is on 2 of our India lists: Dividend stocks and Pharma stocks. - [Dividend stocks Regular dividend yield (%): 2.66](https://www.sectoralpha.in/dividend-stocks-india)
- [Pharma stocks Market value (₹ crore): 9674.449166740147](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Procter & Gamble Health profitable? Procter & Gamble Health Ltd earned ₹96.0 Cr of net profit in the Jun 2026 quarter, +45.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year Mar 2026 profit was ₹327 Cr. Over 10 years profit has grown 15.3% a year on average. That is 26.4% of the quarter's revenue. The same quarter a year earlier earned ₹66.0 Cr. For the full year, Mar 2026 profit was ₹327 Cr (+39.7% on the year before). Why profit moved: revenue changed +7.4% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +23.9% and revenue +12.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY26-Q4. revenue ₹370 Cr and profit ₹95 Cr as reported. FY27-Q1. revenue ₹364 Cr and profit ₹96 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much revenue does Procter & Gamble Health make, and is it growing? Procter & Gamble Health Ltd reported ₹364 Cr of revenue in the Jun 2026 quarter, +7.4% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 3.6% a year on average. The last full year, Mar 2026, came in at ₹1,408 Cr. Why this happened. Management cited superior brand-building activities and product innovations in the preventive healthcare segment driving 19% YoY sales growth in Q4 FY26. The last four reported quarters add to ₹1,433 Cr. Mar 2026 revenue was ₹1,408 Cr, +50.7% on the year before. Recent pace: the last four quarters grew +12.7% on average, against 3.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.6%, against +11.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +19.3%, against +33.1% a year (rolling over). FY26-Q4. revenue ₹370 Cr and profit ₹95 Cr as reported. FY27-Q1. revenue ₹364 Cr and profit ₹96 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Procter & Gamble Health keep? Procter & Gamble Health Ltd's operating margin was 27.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 7.0% and 34.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. FY26-Q4. revenue ₹370 Cr and profit ₹95 Cr as reported. FY27-Q1. revenue ₹364 Cr and profit ₹96 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## Is Procter & Gamble Health's profit turning into cash? Over the last 3 years, 96% of Procter & Gamble Health Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In Mar 2026 it brought in ₹338 Cr of operating cash against ₹327 Cr of profit. After ₹13.0 Cr of spending on assets, ₹325 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 96% of profit came in as cash: the cash cycle got 36 days longer between Jun 2021 and Mar 2026, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Procter & Gamble Health's cash go? Procter & Gamble Health Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −13 days in Mar 2026, up from −49 days in Jun 2021. It spent ₹49.0 Cr on assets over the last 3 years. Customers take 43 days to pay, and stock sits for 137 days on average. At Mar 2026 sales of ₹1,408 Cr, each day of that cycle ties up about ₹3.9 Cr, so roughly −₹50.0 Cr is tied up in the business at any time. Mar 26: customers took 43 days to pay and stock sat for 137 days, about 4.5 months of sales sitting as stock, for a full cycle of −13 days, longer than Jun 2021's −49. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 137 days. Customers pay about 43 days after that. Suppliers are paid at 192 days. Together that makes the −13-day cycle. Spending on assets: ₹49.0 Cr over the last 3 years, against ₹79.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹14.0 Cr (Mar 2026): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Procter & Gamble Health's P/E ratio, and how does it compare with its own history? Procter & Gamble Health Ltd's P/E is 29.1×, near the low end of its own history: it has been lower only 32% of the time. Its usual P/E (the middle reading) is 35.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹214.99. Why the multiple is where it is: over the past year earnings per share moved +39.5% while the price moved −5.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +1.5% a year; about +13.5% a year came from earnings growth and about −12.0 percentage points from the multiple (the market paying less); over 10 years the price moved +22.1% a year; about +16.2% a year came from earnings growth and about +5.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Procter & Gamble Health share price assume? Worked out from its price on 20 July 2026, Procter & Gamble Health Ltd's share price assumed profit growth of about 19.5% a year. Over the past 10 years its profit actually grew 15.3% a year. Today its P/E is 29.1×, lower than 68% of its own last 11 years. This is a one-day reading, taken on 20 July 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Procter & Gamble Health business getting better or worse? Procter & Gamble Health Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +40.8% at its peak to +19.3%, but the business is still expanding, with ROCE rising at 84.1%. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the Procter & Gamble Health story, and has it been checked? Procter & Gamble Health Ltd's story is not scored yet against the checks our research set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Sustained OPM at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical. Our read, 19 July 2026. From the numbers. From the price. Price stage 4, week 4, below its 200-day line, relative strength rising. From the research. Where they disagree. What is proven. What is not proven yet. Sustained OPM at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical. What would change our mind. Sustained OPM at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical. The test written in advance. Sustained OPM at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical. Measured by: the thesis as written as stated by the next result. What the company does. With margins at cycle highs, any pricing pressure or input cost inflation will severely compress earnings. What the surface reading misses. The surface reading is: PAT growth of 56% looks like a massive acceleration. The research reads it further: Growth is entirely margin-led, as OPM expanded to 37%. What the surface reading misses. Sources: our stock research file (19 July 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## How much does Procter & Gamble Health earn on its capital? Procter & Gamble Health Ltd earned a ROCE of 84% in Mar 2026. That is up from a low of 12% in FY14. Its return on capital used (ROIC) is 89.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 23.2% net margin and 1.67× asset turnover (sales divided by assets). Why the return is what it is (Mar 2026): a 23.2% net margin × 1.67× asset turnover × 1.60× leverage (assets divided by equity) ≈ 62.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 101.0% − 12.0% = +89.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 101.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 87.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Procter & Gamble Health have too much debt? Procter & Gamble Health Ltd has total debt of ₹9.0 Cr against shareholder equity of ₹525 Cr as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Procter & Gamble Health shareholding pattern? Domestic institutions cut their stake in Procter & Gamble Health Ltd by 2.2 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 12.6% of the company. Foreign institutions moved −0.2 points over the same period, to 6.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −2.2 points over 8 quarters, to 12.6%; Foreign institutions: −0.2 points over 8 quarters, to 6.4%; Promoters: +0.0 points over 8 quarters, to 51.8%. Why the owners changed: domestic institutions drove it (−2.2 points). They reduced their stake. ## How far is Procter & Gamble Health from balance-sheet trouble? For Procter & Gamble Health Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Procter & Gamble Health rank in its industry? 65.8 out of 100, rank 1 of 8 in Pharma - MNC bulk Drugs, with 81% of the evidence available. Procter & Gamble Health Ltd scores 65.8 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 24.1 + 16.6 + 13.1 + 12 = 65.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Procter & Gamble Health compared with? Procter & Gamble Health ranks 1 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 65.8 out of 100. 1. Procter & Gamble Health Ltd this page PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) GLAXO · losing its lead · Evidence leans up · 96% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.1/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.1 + 6.4 + 15.2 = 58.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) PFIZER · quiet · Evidence leans up · 96% evidence 52.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.7/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.7 + 19.6 + 3.4 = 52.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Procter & Gamble Health in size? Procter & Gamble Health is the 5th largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Glaxosmithkline Pharmaceuticals, Pfizer and Astrazeneca Pharma India. Just below it: Sanofi Consumer Healthcare India, Sanofi India and Novartis India. ### Pharma - MNC bulk Drugs companies close in size

1. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) ₹42,255 crore
2. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹16,871 crore
3. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
4. Procter & Gamble Health Ltd ₹9,413 crore
5. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) ₹7,928 crore
6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) ₹7,379 crore
7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) ₹4,179 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [Elecon Engineering Company Ltd](https://www.sectoralpha.in/stocks/elecon-engineering-company-ltd) ₹9,419 crore · Capital Goods - Mining Equipement
2. [Powergrid Infrastructure Investment Trust](https://www.sectoralpha.in/stocks/powergrid-infrastructure-investment-trust) ₹9,417 crore · Infrastructure Investment Trusts
3. Procter & Gamble Health Ltd ₹9,413 crore
4. [SBFC Finance Ltd](https://www.sectoralpha.in/stocks/sbfc-finance-ltd) ₹9,381 crore · Finance & Investments - MSME Lending
5. [Lloyds Enterprises Ltd](https://www.sectoralpha.in/stocks/lloyds-enterprises-ltd) ₹9,323 crore · Trading

## What else do people ask about Procter & Gamble Health? ### What is Procter & Gamble Health's share price today? Procter & Gamble Health Ltd's share price is ₹5,859.00, −5.0% over the past year. The whole company is worth ₹9,727 Cr on the market. In the last 52 weeks it traded between ₹4,779 to ₹6,839; today it is 52% of the way up from the low, 3.3% above its 200-day average (as of 3 November 2026). ### What were Procter & Gamble Health's latest quarterly results? Procter & Gamble Health Ltd reported revenue of ₹364 Cr and net profit of ₹96.0 Cr for the Jun 2026 quarter. Revenue rose 7.4% and profit rose 45.5% compared with a year earlier. Earnings per share were ₹57.92 (as of 3 November 2026). ### What is Procter & Gamble Health's market cap? Procter & Gamble Health Ltd's market capitalisation is ₹9,727 Cr at a share price of ₹5,859.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Procter & Gamble Health performing? Procter & Gamble Health Ltd's share price has been falling for 4 weeks. In its latest quarter, revenue rose 7.4% and profit rose 45.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will Procter & Gamble Health's share price go up? This page does not forecast Procter & Gamble Health Ltd's share price. What it shows instead: the share price is ₹5,859.00, and it has been falling for 4 weeks. Its P/E of 29.1× is higher than 32% of its own last 11 years (as of 3 November 2026). ### Who owns Procter & Gamble Health? Promoters own 51.8% of Procter & Gamble Health Ltd, foreign institutions 6.4%, domestic institutions 12.6% and the public 29.1% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 2.2 percentage points over 8 quarters (as of 3 November 2026). ### Where is Procter & Gamble Health in its business cycle? Procter & Gamble Health Ltd's Mar 2026 operating margin was 33.0%, against a 13-year range of 7.0% to 34.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 27.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Procter & Gamble Health story? The main question: yearly earnings per share moved +39.5% while the share price moved −5.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Procter & Gamble Health a stock worth studying right now? What the numbers show: Procter & Gamble Health Ltd's earnings have grown faster than its share price. Earnings per share grew +39.5% in a year while the price moved −5.0%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Procter & Gamble Health share price forecast for 2026? What management itself guided: Growth momentum expected sustainable through near-term. What would change the story: Sustained operating margin at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical. ## Lists

- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.